[go: up one dir, main page]

AR002069A1 - STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS. - Google Patents

STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.

Info

Publication number
AR002069A1
AR002069A1 ARP960102657A AR10265796A AR002069A1 AR 002069 A1 AR002069 A1 AR 002069A1 AR P960102657 A ARP960102657 A AR P960102657A AR 10265796 A AR10265796 A AR 10265796A AR 002069 A1 AR002069 A1 AR 002069A1
Authority
AR
Argentina
Prior art keywords
stable
solutions
erythromicilamine
concentrated
erythromycylamine
Prior art date
Application number
ARP960102657A
Other languages
Spanish (es)
Inventor
Stefan Dr Leiner
Werner Dr Schleicher
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR002069A1 publication Critical patent/AR002069A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una solución estable de eritromicilamina obtenida por disolución de la eritrocilamina en un medio acuoso tamponado a temperatura ambiente con valoresde pH entre 5 y 8 empleando preferentemente un sistema de tampón de fosfato. En estascondicione s la concentración de eritromicilamina puede estarcomprendida entre 5 y 40% en peso. La solución obtenida se esteriliza por filtración en condiciones asépticas. En estas condiciones las soluciones deeritromicilamina son estables ypueden emplea rse en medicina veterinaria en terapia e infecciones.A stable erythromycylamine solution obtained by dissolving erythrocylamine in a buffered aqueous medium at room temperature with pH values between 5 and 8, preferably using a phosphate buffer system. Under these conditions, the concentration of erythromycylamine can be between 5 and 40% by weight. The obtained solution is sterilized by filtration under aseptic conditions. Under these conditions, the erythromycylamine solutions are stable and can be used in veterinary medicine for therapy and infections.

ARP960102657A 1995-05-23 1996-05-22 STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS. AR002069A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19518917A DE19518917A1 (en) 1995-05-23 1995-05-23 Stable, concentrated, locally tolerated erythromycylamine solutions

Publications (1)

Publication Number Publication Date
AR002069A1 true AR002069A1 (en) 1998-01-07

Family

ID=7762671

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102657A AR002069A1 (en) 1995-05-23 1996-05-22 STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.

Country Status (6)

Country Link
AR (1) AR002069A1 (en)
AU (1) AU5898296A (en)
DE (1) DE19518917A1 (en)
IL (1) IL118381A0 (en)
WO (1) WO1996037190A1 (en)
ZA (1) ZA964082B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723447A (en) * 1996-07-02 1998-03-03 Rhone Merieux, Inc. Water miscible erythromycin solutions
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA695765B (en) * 1968-08-29 1971-03-31 Lilly Co Eli Erythromycylamine and process for preparing same
ZA71763B (en) * 1970-04-13 1972-03-29 Lilly Industries Ltd Erythromycylamines via hydrazones
ZA87591B (en) * 1986-02-03 1988-09-28 Lilly Co Eli Novel derivatives of eryhromycylamine
US5110800A (en) * 1986-02-18 1992-05-05 Eli Lilly And Company Derivatives of erythromycylamine
DE4410637C1 (en) * 1994-03-26 1995-09-21 Boehringer Ingelheim Vetmed Injectable solutions of dirithromycin

Also Published As

Publication number Publication date
ZA964082B (en) 1996-11-22
IL118381A0 (en) 1996-09-12
DE19518917A1 (en) 1996-11-28
AU5898296A (en) 1996-12-11
WO1996037190A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
MX9401396A (en) OSMOTIC HATCHABLE ECLOSIONABLE DISTRIBUTOR DEVICES ACTIVATED BY THE PH.
ES2077554T1 (en) USEFUL AQUEOUS INJECTABLE FORMULATIONS FOR A RADIO-DIAGNOSIS INCLUDING AROMATIC IODATE COMPOUNDS USED AS A X-RAY CONTRASTING MEDIA.
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
BG98902A (en) IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKIN INHIBITORS
DE3869872D1 (en) LYOPHILIZED PHARMACEUTICAL PREPARATION OF A NEOCARCINOSTAT DERIVATIVE.
DK0633721T3 (en) Platelet purification with the 8-methoxypsoralen
BR9702362A (en) New stable liquid formulas based on paracetamol and its preparation.
EP1025846A4 (en) AQUEOUS LIQUID PREPARATIONS
ES2108592T3 (en) THICKENED COMPOSITION IN AQUEOUS MEDIUM AND THICKENING PROCEDURE OF A WATERY MEDIA.
BR0014820A (en) Dialysis solution including polyglycol osmotic agent, and its use
IT1303671B1 (en) SALTS OF NITRIC ACID WITH ACTIVE DRUGS IN THE TREATMENT OF DISEASES OF THE RESPIRATORY SYSTEM
ES8801580A1 (en) A PROCEDURE FOR PRODUCING A STERILE PYROGEN-FREE ANTHRACICLINE GLYCOSIDE SOLUTION
BR9506840A (en) Pharmaceutical preparation containing plasminogen activators
ES2079327A1 (en) Pharmaceutical formulations of cefaclor
AR002069A1 (en) STABLE, CONCENTRATED AND LOCALLY COMPATIBLE ERYTHROMICILAMINE SOLUTIONS.
EP0200157A3 (en) Use of an aqueous stabilized chlorite matrix solution in infectious conditions
ATE61522T1 (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF TINEA PEDIS.
HUP0302310A2 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
BR9611588A (en) Use of flupirtine in the prophylaxis and therapy of diseases associated with damage to the hematopoietic cellular system
RU2003122531A (en) METHOD FOR CULTIVATION OF NITROFIXING BACTERIA
NO902607L (en) Crystalline CEFEM ACID ADDITION SALTS AND PROCEDURES FOR PREPARING THEREOF.
ES2091764T3 (en) WATER PURIFICATION SYSTEM.
ES2122962T3 (en) OPTICALLY ACTIVE ALKYLENE-DIOXYBENZENE DERIVATIVES AND THEIR USE IN THERAPY.
ES2060057T3 (en) AQUEOUS SOLUTIONS CONTAINING PROTEIN.
NO971604L (en) Oral sabeluzole suspensions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal